Drugs / mixed salts amphetamine
mixed salts amphetamine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT06853665 | Feb 2026 → Feb 2030 expected | attention deficit-hyperactivity disorder, autism | Gagan Joshi | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02058693 Comparator | Dec 2010 → Dec 2014 | major depressive disorder | Rush University Medical Center | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mixed salts amphetamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02058693 ↗ |
| Known as | Adderall XR | “Adderall XR (mixed salts amphetamine)” NCT06853665 ↗ |
| Known as | MAS | “Mixed Amphetamine Salts (MAS) (also known as Adderall XR)” NCT06853665 ↗ |
| Known as | Mixed Amphetamine Salts | “Mixed Amphetamine Salts (MAS) (also known as Adderall XR)” NCT06853665 ↗ |
| Known as | MSA | “we will study the safety, tolerability and efficacy of mixed salts amphetamine (MSA), trade name Adderall, augmentation of antidepressant therapy for Major Depressive Disorder (MDD)” NCT02058693 ↗ |